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Abstract Circulating oxidized LDL (oxLDL) levels are
strongly correlated to LDL-cholesterol (LDL-c) and apolipo-
protein-B100 (apoB100), making it difficult to disentangle
their independent contributions to cardiovascular risk. We
explored the determinants of oxLDL and the relation be-
tween oxLDL and flow-mediated dilation (FMD) of the bra-
chial artery to investigate whether the oxLDL/LDL-c and
oxLDL/apoB100 ratios are more informative than the sep-
arate variables. FMD of the brachial artery and plasma con-
centrations of oxLDL, LDL-cholesterol, and apoB100 were
measured in 624 men and women (age range 50 to 87 years),
participating in a population-based cohort study. OxLDL
was strongly correlated with apoB100 (r 5 0.82, P , 0.001)
and LDL-c (r 5 0.67, P , 0.001). Other major independent
determinants of oxLDL were sex, HDL-cholesterol, and LDL
particle size. LDL-c and apoB100 concentrations were not
significantly associated with FMD. After adjustment for
age, sex, glucose tolerance status, and Framingham risk
score, the oxLDL/apoB100 ratio was negatively related to
FMD (P 5 0.017). This association was weaker for the
oxLDL/ LDL-c ratio (P 5 0.062) and absent for oxLDL
level (P 5 0.27). In contrast to oxLDL, the oxLDL/
apoB100 ratio, and to a lesser extent the oxLDL/LDL-c ratio,
are related to a functional measure of atherosclerosis. There-
fore correction of oxLDL for LDL particle number may
improve the clinical usefulness of oxLDL measurement.—
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Atherosclerosis is considered a process involving the in-
terplay of inflammation and oxidative stress. Oxidation of
LDL and the subsequent uptake by macrophages in the
vascular wall are important steps in the development of
atherosclerosis (1). A small part of the oxidized LDL
(oxLDL) particles escapes uptake by macrophages and re-
turns to the blood stream or may leak from atherosclerotic
plaques. Thus, measuring circulating levels of oxLDL may
contribute to the estimation of cardiovascular disease
(CVD) risk. In support of this notion, concentrations of
oxLDL were elevated in patients with stable and unstable
angina and acute myocardial infarction (2). In apparently
healthy middle-aged men, oxLDL was found to be a strong
predictor for acute coronary heart disease events (3).
The concentration of oxLDL depends not only on the
degree of oxidative stress, but also on the amount of sub-
strate for oxidation (i.e., the number of LDL particles). In-
deed, oxLDL levels were consistently found to be strongly
correlated to LDL-cholesterol (LDL-c) and apolipoprotein-
B100 (apoB100) in several studies (3–8), making it diffi-
cult to disentangle their separate contributions to CVD.
Therefore, to establish the additional value of oxLDL in
the assessment of CVD risk, it may be necessary to account
for the number of LDL particles. LDL-c and apoB100 have
been used for this purpose, but their merits have never
been compared.
Impaired flow-mediated dilation (FMD) of the brachial
artery has been shown to predict future cardiovascular
events (9, 10). Previous studies have investigated the re-
lationship between oxLDL and FMD in specific patient
populations (11–13), but this relation has not yet been
evaluated in a large-population-based sample. We have
used FMD data from the Hoorn Study, a community-based
cohort study among elderly men and women, to assess the
suitability of the oxLDL/LDL-c and oxLDL/apoB100 ra-
tios to correct for LDL particle number. We have explored
the determinants of oxLDL and the relations between
oxLDL and the oxLDL/LDL-c and oxLDL/apoB100 ratios
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with FMD to establish whether these ratios provide infor-
mation beyond the separate variables.
MATERIALS AND METHODS
Subjects
The present investigation was conducted in the 2000 follow-up
examination of the Hoorn Study (14) and the Hoorn Screening
Study (15), both of which were population-based studies in Cau-
casians. From the study population (n 5 822), we excluded per-
sons using lipid-lowering medication (n 5 134) and with missing
data on primary variables of interest (n 5 64), leaving 624 in-
dividuals (300 men and 324 women), of whom 233 had normal
glucose metabolism, 159 impaired glucose metabolism, and 232
type 2 diabetes according to WHO-99 criteria (16). The local ethics
committee approved the study and all participants gave their writ-
ten informed consent.
Plasma lipids and apoB100
LDL-c was directly determined by the “N-geneous” assay
(GenZyme, Cambridge, MA). Intra- and interassay coefficients
of variation (CV) were 0.7% and 2.7%, respectively. Triglyceride
concentrations up to 13.5 mmol/L do not interfere with this as-
say. Total and HDL-cholesterol (HDL-c) and triglycerides were
measured by standard enzymatic methods (Roche, Mannheim,
Germany). ApoB100 concentrations were determined nephelomet-
rically using an “Immage 800” immunochemistry system (Beckman
Coulter Inc., Fullerton, CA) with intra- and interassay CVof 4.9%
and 5.1%, respectively.
In vivo oxLDL
A competitive ELISA (Mercodia, Uppsala, Sweden) was used to
determine oxLDL concentrations in EDTA-plasma. The 4E6-
monoclonal antibody of the assay is directed against apoB100
with at least 60 lysines substituted by aldehydes (2) and is highly
specific for oxLDL (17). Intra- and interassay CV were 6.7% and
7.0%, respectively. To estimate the extent of LDL oxidation, the
ratio of oxLDL to LDL-c and the ratio of oxLDL to apoB100 were
calculated. These estimates were expressed as U/mmol LDL-c
and U/g apoB100, respectively.
LDL particle size and in vitro oxidizability
LDL was isolated by ultracentrifugation between densities
1.019 and 1.063 kg/L. LDL particle size was determined by high-
performance gel-filtration chromatography as described pre-
viously, using thyroglobulin (17.0 nm) and fibrinogen (22.2 nm)
as calibrators (18). Intra- and inter-assay CV were 0.1% and
0.2%, respectively.
The susceptibility of LDL to in vitro oxidation was determined
by measurement of conjugated dienes, after addition of copper
ions as pro-oxidant, as previously described (19). The resistance
of LDL to oxidation was expressed as lag time (min). The intra-
and interassay CV were 1.6% and 3.6%, respectively.
Glucose metabolism parameters
HbA1c was analyzed by ion exchange high-performance liquid
chromatography (Bio-Rad, Veenendaal, The Netherlands). Fast-
ing glucose was measured enzymatically (Roche, Mannheim,
Germany) and fasting insulin with a double-antibody radioimmu-
noassay (Linco Research, St. Louis).
TABLE 1. Subject characteristics in tertiles of oxidized LDL (oxLDL)
Unit Overall 1st tertile 2nd tertile 3rd tertile P for trend
OxLDL, range U/L ,57.6 57.6–71.3 .71.3
Number 624 208 208 208
Age years 69.0 (7.3) 69.1 (7.6) 69.7 (7.4) 68.3 (6.6) 0.22
Female sex % 52 46 53 57 0.019
ApoB100 g/L 1.04 (0.23) 0.85 (0.15) 1.03 (0.15) 1.26 (0.19) ,0.001
LDL-c mmol/L 3.8 (0.9) 3.1 (0.7) 3.7 (0.6) 4.4 (0.8) ,0.001
HDL-c mmol/L 1.39 (0.40) 1.50 (0.43) 1.42 (0.40) 1.25 (0.34) ,0.001
Triglyceridesa mmol/L 1.3 (1.0–1.8) 1.1 (0.8–1.4) 1.3 (1.0–1.7) 1.8 (1.3–2.4) ,0.001
Total cholesterol mmol/L 5.8 (1.0) 5.1 (0.8) 5.8 (0.8) 6.5 (0.9) ,0.001
LDL particle size nm 21.49 (0.45) 21.60 (0.38) 21.55 (0.42) 21.32 (0.51) ,0.001
LDL oxidizability min 72.0 (9.7) 72.7 (9.9) 71.4 (9.0) 71.9 (10.2) 0.41
Glucose metabolism
- Impaired % 25.5 26.9 20.2 29.3 0.57
- Type 2 diabetes % 37.2 34.6 38.0 38.9 0.36
HbA1c % 6.1 (0.8) 6.0 (0.7) 6.0 (0.6) 6.2 (0.9) 0.005
Fasting glucosea mmol/L 6.0 (5.5–6.9) 6.0 (5.5–6.7) 6.0 (5.5–7.0) 6.2 (5.6–7.2) 0.018
Insulina pmol/L 60 (42–88) 55 (40–78) 61 (43–91) 65 (45–94) 0.002
C-reactive proteina mg/L 2.3 (1.1–4.8) 1.8 (1.0–3.4) 2.3 (1.0–4.5) 2.7 (1.4–6.5) ,0.001
Serum albumin g/L 42 (40–43) 42 (40–43) 41 (40–43) 41 (40–43) 0.20
BMI kg/m2 27.6 (4.3) 26.9 (4.3) 27.6 (4.1) 28.3 (4.4) ,0.001
Waist circumference cm 96.1 (12.5) 94.4 (12.3) 95.6 (12.2) 98.2 (12.7) 0.002
DBP mmHg 83 (11) 83 (10) 83 (11) 83 (11) 0.47
SBP mmHg 142 (21) 141 (18) 143 (23) 143 (22) 0.38
Alcohol intake
,1 g/day % 29 29 26 31 0.63
1–40 g/day % 64 62 66 63 0.78
.40 g/day % 8 9 7 6 0.18
Current smoking % 17 13 16 20 0.050
(Micro-)albuminuria % 15 14 15 15 0.87
Prior CVD % 44 41 44 48 0.13
ApoB100, apolipoprotein-B100; BMI, body mass index; CVD, cardiovascular disease. Values are displayed either as means (SD), medians (inter-
quartile range), or percentages.
a Variables were log-transformed prior to linear trend analysis.
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Measurement of endothelium-dependent and
endothelium-independent dilation
Ultrasound examination of the right brachial artery was per-
formed according to the guidelines of the International Brachial
Artery Reactivity Task Force (20). Baseline diameter, blood flow
(peak systolic velocity), FMD, and nitroglycerin-mediated dilation
(NMD) were determined by one single observer (RMAH) as
previously described (21). The intraobserver CV were 4.3% for
diameter, 14.7% for FMD, and 10.3% for NMD (21). Of the
624 participants, qualitatively satisfactory ultrasound examina-
tions were obtained in 484 individuals. Poor definition of the ar-
terial wall due to obesity and inability to remain motionless due to
muscoskeletal disorders were the main reasons for missing ultra-
sound data (21).
Other measurements
Plasma C-reactive protein (CRP) was measured with a highly
sensitive in-house sandwich enzyme-linked immunosorbent assay
(22). Data on smoking habits and alcohol consumption were
obtained by a questionnaire. Microalbuminuria was defined as
urinary albumin-creatinine ratio >2 mg/mmol. Prior CVD was
defined as Minnesota Code 1.1–1.3, 4.1–4.3, 5.1–5.3, or 7.1 on
the electrocardiogram or coronary bypass operation or angio-
plasty, or an ankle-brachial blood pressure index ,0.9 in either
leg, peripheral arterial bypass, or amputation for atherosclerotic
disease. The Framingham risk score was calculated (23).
Statistical analyses
Data are presented as mean (SD) or median (interquartile
range). Skewed variables were log-transformed prior to trend
analyses and multiple linear regression analyses. In regression
models for FMD, we considered age, sex, glucose tolerance status,
baseline diameter, and the increase in peak systolic velocity as
standard correction variables. In models for NMD, age, sex, glu-
cose tolerance status, and baseline diameter were included. P ,
0.05 was considered to indicate statistical significance. All analyses
were performed using SPSS software, version 15 (SPSS Inc., Chi-
cago, IL).
RESULTS
Subject characteristics
The characteristics of the subjects by tertiles of circu-
lating oxLDL levels are shown in Table 1. With increas-
ing oxLDL concentrations, the percentage of women,
apoB100, LDL-c, triglycerides, total cholesterol, HbA1c,
fasting glucose, insulin, CRP, body mass index, and waist
circumference increased significantly, while a decreasing
trend was observed for HDL-c and LDL-size. Current smok-
ing status tended to a significant positive relationship with
oxLDL. There were no significant linear trends for age,
LDL in vitro oxidation, serum albumin, blood pressure, al-
cohol consumption, microalbuminuria, and prior CVD
across the oxLDL tertiles.
Adjustment of oxLDL for particle number
The trends with oxLDL shown in Table 1 were con-
firmed by linear regression analysis after adjustment for
age and sex (Table 2). The associations of oxLDL with
apoB100 and LDL-c were particularly strong, reflecting
the fact that the total amount of LDL is an important de-
terminant of oxLDL concentration (Table 2 and Fig. 1).
To correct oxLDL levels for LDL particle number, the
oxLDL/LDL-c and oxLDL/apoB100 ratios were calculated.
TABLE 2. Age and sex adjusted associations with oxLDL, and the oxLDL/LDL-c and oxLDL/apoB100 ratios
OxLDL OxLDL/LDL-c OxLDL/apoB100
Variable Units or categories st. b P st. b P st. b P
Age Years 20.085 0.033 20.082 0.042 20.031 0.45
Sex Female vs. male 0.110 0.006 20.054 0.18 20.037 0.36
OxLDL U/L 0.323 ,0.001 0.322 ,0.001
ApoB100 g/L 0.815 ,0.001 20.033 0.42 20.275 ,0.001
LDL-c mmol/L 0.671 ,0.001 20.443 ,0.001 20.222 ,0.001
HDL-c mmol/L 20.389 ,0.001 20.348 ,0.001 20.220 ,0.001
Triglyceridesa mmol/L 0.541 ,0.001 0.390 ,0.001 0.156 ,0.001
Total cholesterol mmol/L 0.715 ,0.001 20.276 ,0.001 20.229 ,0.001
LDL particle size nm 20.367 ,0.001 20.503 ,0.001 20.240 ,0.001
LDL oxidizability (lagtime) min 20.003 0.95 0.081 0.044 0.064 0.11
Glucose metabolism Impaired vs. normal 0.102 0.022 0.062 0.16 0.060 0.18
Diabetes vs. normal 0.107 0.016 0.265 ,0.001 0.172 ,0.001
HbA1c % 0.147 ,0.001 0.202 ,0.001 0.123 0.002
Fasting glucosea mmol/L 0.141 ,0.001 0.243 ,0.001 0.141 ,0.001
Insulina pmol/L 0.147 ,0.001 0.288 ,0.001 0.166 ,0.001
C-reactive proteina mg/L 0.148 ,0.001 0.236 ,0.001 0.127 ,0.002
Serum albumin g/L 20.041 0.31 20.059 0.15 20.170 ,0.001
BMI kg/m2 0.143 ,0.001 0.139 ,0.001 0.118 0.003
Waist circumference cm 0.181 ,0.001 0.185 ,0.001 0.145 ,0.001
Diastolic blood pressure mmHg 0.045 0.26 0.064 0.11 0.027 0.50
Systolic blood pressure mmHg 0.046 0.26 0.072 0.078 0.012 0.76
Alcohol intake 1–40 g/day 20.008 0.85 20.134 0.003 20.142 0.002
.40 g/day 20.003 0.95 0.040 0.38 20.026 0.57
Current smoking Yes vs. no 0.077 0.055 0.051 0.20 0.046 0.25
Regression coefficients are presented as standardized b.
a Variables were log-transformed prior to analyses.
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Determinants of oxLDL
The variables associated with oxLDL/LDL-c and oxLDL/
apoB100 ratios in linear regression analyses were identical
to the variables associated with oxLDL, with a few excep-
tions (Table 2). The positive association with female sex
was lost, and moderate alcohol intake (1–40 g/day) was neg-
atively associated with both ratios. Furthermore, the oxLDL/
apoB100 ratio was negatively associated with serum albumin.
To establish which variables other than LDL-c and
apoB100 were independent determinants of (adjusted)
oxLDL, we explored multivariate linear regression models
with oxLDL, the oxLDL/LDL-c ratio, and the oxLDL/
apoB100 ratio as dependent variables (Table 3). In all
models, an identical set of potential predictor variables, ex-
cluding apoB100 and LDL-c, was used. Determinants other
than age and sex were selected because of significant uni-
variate associations and/or biological plausibility. Cate-
gories of glucose metabolism were used as a proxy for all
variables associated with glucose metabolism. Because tri-
glycerides were strongly associated with LDL particle size
(r 5 20.67; P , 0.001), only the latter was included in
the models. LDL particle size was the only independent
variable shared by all three models. Female sex and low
HDL-cholesterol were additional major determinants of
oxLDL. Additional independent determinants of the
oxLDL/LDL-c and oxLDL/apoB100 ratios were high CRP
and low serum albumin, respectively. Furthermore, a weak
negative association between moderate alcohol intake and
the oxLDL/apoB100 ratio was observed. Age, categories
of glucose metabolism, waist circumference, and current
smoking did not significantly contribute to any of the mod-
els. The full models explained 20%, 28%, and 11% of the
variability of oxLDL, oxLDL/LDL-c, and oxLDL/apoB100,
respectively. If LDL-c or apoB100 were added as indepen-
dent variables to the regression model for oxLDL, the ex-
plained variance increased to 63 and 71%, respectively.
OxLDL and vascular function
Neither LDL-c nor apoB100 were associated with FMD
in unadjusted analysis or after adjustment for the standard
variables age, sex, baseline diameter, glucose tolerance sta-
tus, and increase in peak systolic velocity (all P . 0.5).
Mean FMD values did not significantly differ between sub-
jects with levels of oxLDL below or above the median value
(Table 4 and Fig. 2A). In contrast, if the study population
TABLE 3. Multivariable linear regression models for oxLDL, the oxLDL/LDL-c ratio,
and the oxLDL/apoB100 ratio
OxLDL OxLDL/LDL-c oxLDL/apoB100
Independent variable Units of increase or categories st. b P st. b P st. b P
Age Years 20.060 0.12 20.052 0.16 20.042 0.31
Sex Female vs. male 0.30 ,0.001 0.059 0.16 0.028 0.54
Glucose metabolism Impaired vs. normal 0.032 0.45 20.029 0.47 0.016 0.73
Diabetes vs. normal 20.078 0.10 0.061 0.18 0.083 0.10
Waist circumference cm 0.066 0.14 20.019 0.66 0.046 0.33
LDL particle diameter nm 20.25 ,0.001 20.43 ,0.001 20.16 0.003
HDL-cholesterol mmol/L 20.24 ,0.001 20.039 0.43 20.072 0.20
C-reactive protein mg/L, log transformed 0.024 0.58 0.11 0.006 20.010 0.82
Serum albumin g/L 20.020 0.61 20.059 0.12 20.18 ,0.001
Current smoking Yes vs. no 0.047 0.21 0.030 0.40 0.027 0.50
Alcohol intake 1–40 g/day 0.054 0.20 20.052 0.19 20.088 0.047
.40 g/day 0.017 0.70 0.036 0.40 20.004 0.93
R2 model 0.20 0.28 0.11
Regression coefficients are presented as standardized b; independent variables significantly contributing to the
models are printed in bold.
Fig. 1. The association between oxidized LDL and LDL choles-
terol (A) and the association between oxidized LDL (oxLDL) and
apolipoprotein-B100 (apoB100) (B).
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was dichotomized according to the oxLDL/LDL-c ratio or
oxLDL/apoB100 ratio, the mean FMD was approximately
15% lower in subjects with values of these ratios above the
median (Fig. 2B, C). To investigate whether the rela-
tionship between (adjusted) oxLDL and FMD was inde-
pendent of traditional risk factors, several multiple linear
regression models were explored (Table 5). After adjust-
ment for standard variables, oxLDL was negatively related
to FMD, but this association lost significance upon adjust-
ment for prior CVD or Framingham risk score. The oxLDL/
LDL-c ratio was negatively related to FMD with borderline
significance, in the standard model and after additional
adjustment. In contrast, the negative association between
the oxLDL/apoB100 ratio and FMD remained highly sig-
nificant after adjustment for prior CVD, Framingham risk
score, microalbuminuria, and waist circumference. Mean
NMD values did not significantly differ between subjects
with levels of oxLDL below or above the median value (Ta-
ble 4). In linear regression models, neither oxLDL nor the
oxLDL/LDL-c and oxLDL/apoB100 ratios were associated
with NMD (all P . 0.3), and the negative associations be-
tween these variables and FMD were not attenuated after
adjustment for NMD (Table 5, models 5 and 7).
DISCUSSION
The present study shows that the total amount of LDL,
either expressed as LDL-c or as apoB100 level, is by far the
strongest determinant of oxLDL levels. In contrast to
LDL-c, apoB100 and oxLDL concentrations; the oxLDL/
LDL-c ratio; and, more prominently, the oxLDL/apoB100
ratio, independent of traditional risk factors, were related
to endothelium-dependent dilation of the brachial artery.
Correction of oxLDL for LDL particle number may thus
improve the clinical usefulness of oxLDL measurement.
OxLDL concentrations not only depend on the level of
oxidative stress, but also on the amount of substrate for
oxidation (i.e., the total amount of LDL or the number
of LDL particles). Because it is difficult to exactly deter-
mine the number of LDL particles, both LDL-c and
apoB100 concentrations have been used as estimates (3–
8). Adjustment of oxLDL for either LDL-c or apoB100
may be essential for a correct interpretation of the data,
particularly in intervention studies. For example, Van Tits
et al. (4) observed no effect of statin use on the oxLDL/
Fig. 2. Flow-mediated dilation (FMD) of the brachial artery
according to low (below the median) or high (above the median)
values of oxLDL (A), the oxLDL/LDL-cholesterol (LDL-c) ratio
(B), or the oxLDL/ apoB100 ratio (C). FMD data are presented
as means with 95% confidence intervals. Significance of differences
was tested by Mann-Whitney test.
TABLE 4. Brachial artery characteristics according to levels of
oxidized LDL (oxLDL)
OxLDL
Below median
,64 U/L
Above median
.64 U/L P
N 244 240
Diameter (mm)
Baseline 4,687 (768) 4,599 (702) 0.20
After FMD 4,866 (789) 4,768 (709) 0.18
After NMD 5,131 (803) 5,030 (707) 0.18
Absolute change in diameter (mm)
After FMD 177 (171) 171 (145) 0.70
After NMD 453 (214) 448 (217) 0.62
Percentage change in diameter (%)
After FMD 3.96 (3.74) 3.87 (3.36) 0.99
After NMD 10.17 (5.77) 10.07 (5.87) 0.85
Peak systolic velocity (cm/s)
Baseline 58 (13) 57 (12) 0.40
After reactive hyperemia 105 (25) 105 (26) 0.68
% Increase 84 (39) 88 (48) 0.62
Results are expressed as mean (SD). FMD, flow-mediated dilation;
NMD, nitroglycerin-mediated dilation. P values were calculated by
Mann-Whitney analyses.
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apoB100 ratio, although a significant decrease in un-
adjusted oxLDL concentration was observed. Thus, ad-
justments of oxLDL by LDL-c or apoB100 have been
described in several studies, but, to our knowledge, a direct
comparison of both adjustments has been performed in
only one study (8). Both approaches may have some lim-
itations. LDL-c is often estimated with the Friedewald for-
mula, which may lead to reduced accuracy and precision.
However, even if LDL-c is measured directly, as we did, it is
not a perfect measure for LDL particle number, because
LDL particles are heterogeneous and vary in cholesterol
content (24). Due to the fact that each LDL particle con-
tains exactly 1 apoB100 molcule, the apoB100 concen-
tration may be a better estimator for the LDL particle
number. Still, up to approximately 10% of apoB100 mol-
cules is present in VLDL particles (25), resulting in a slight
overestimation of LDL particle number. As illustrated in
Fig. 1, the scatter in the relation between oxLDL and
LDL-c was higher compared with the relation between
oxLDL and apoB100. In agreement with this, the age
and sex adjusted association between oxLDL and apoB100
was stronger than with LDL-c (Table 2). Altogether,
apoB100 seems more suitable than LDL-c for adjustment
of oxLDL.
In sex- and age-corrected analyses, many clinical and
biochemical variables were significantly associated with
oxLDL, and the oxLDL/LDL-c and oxLDL/apoB100 ra-
tios (Table 2). In multivariate linear regression models
with oxLDL, the oxLDL/LDL-c ratio, or the oxLDL/
apoB100 ratio as dependent variable, most of these asso-
ciations lost significance, and only a few independent de-
terminants were identified. LDL particle diameter was by
far the strongest predictor in all three models, in agree-
ment with the observation that small LDL particles are
more prone to oxidation than larger LDL particles (26).
HDL-c was a negative determinant of oxLDL, consistent
with the antioxidative properties of HDL (27). Likewise,
the negative association between serum albumin and the
oxLDL/apoB100 ratio may reflect the antioxidative prop-
erties of albumin. This association may, however, also
reflect the relation between low albumin levels and low-
grade inflammation (28). The strong positive association
between CRP, a marker of inflammation (29), and the
oxLDL/LDL-c ratio confirms that inflammation plays a
role in the process of LDL oxidation.
Type 2 diabetes and variables related to glucose metabo-
lism were positively related to oxLDL (Table 2), consistent
with a role of LDL oxidation in the elevated cardiovascular
morbidity and mortality in diabetes (30, 31). However, dia-
betes was not an independent determinant in the multi-
variate regression models. This may be explained by the
fact that diabetic patients generally have low HDL-c levels
and small LDL particles, both of which were associated
with high oxLDL levels.
Alcohol consumption is related to CVD. Excessive alco-
hol consumption is proatherogenic, while moderate con-
TABLE 5. Multivariable linear regression models with FMD as dependent variable and oxLDL, oxLDL/LDL-c
ratio, or oxLDL/apoB100 ratio as predictor variables
Independent variable Beta (95% confidence interval) P -value
OxLDL, per 1 SD (15.4 U/L)
Standard model 212.8 (225.3 to 20.2) 0.048
Model 1: standard 1 prior CVD 212.1 (224.7 to 0.5) 0.060
Model 2: standard 1 Framingham risk score 28.0 (222.3 to 6.3) 0.27
Model 3: standard 1 (micro)albuminuria 213.2 (225.7 to 20.6) 0.040
Model 4: standard 1 waist circumference 211.1 (223.8 to 1.7) 0.088
Model 5: standard 1 nitroglycerin-mediated dilation 211.8 (223.2 to 20.6) 0.039
Model 6: fully adjusted 27.2 (221.4 to 6.9) 0.32
Model 7: fully adjusted 1 nitroglycerin-mediated dilation 28.1 (220.7 to 4.6) 0.21
OxLDL/LDL-c ratio, per 1 SD (3.8 U/mmol)
Standard model 211.9 (224.3 to 0.5) 0.060
Model 1: standard 1 prior CVD 210.6 (223.1 to 1.8) 0.093
Model 2: standard 1 Framingham risk score 211.8 (224.2 to 0.6) 0.062
Model 3: standard 1 (micro)albuminuria 210.4 (222.8 to 2.1) 0.10
Model 4: standard 1 waist circumference 210.6 (223.1 to 1.9) 0.097
Model 5: standard 1 nitroglycerin-mediated dilation 218.0 (229.1 to 26.9) 0.002
Model 6: fully adjusted 28.3 (220.8 to 4.2) 0.19
Model 7: fully adjusted 1 nitroglycerin-mediated dilation 214.6 (225.8 to 23.4) 0.011
OxLDL/apoB100 ratio, per 1 SD (9.1 U/g)
Standard model 214.9 (227.2 to 22.6) 0.018
Model 1: standard 1 prior CVD 214.3 (226.6 to 22.0) 0.023
Model 2: standard 1 Framingham risk score 214.9 (227.2 to 22.7) 0.017
Model 3: standard 1 (micro)albuminuria 214.0 (226.3 to 21.7) 0.025
Model 4: standard 1 waist circumference 213.8 (226.1 to 21.5) 0.028
Model 5: standard 1 nitroglycerin-mediated dilation 216.9 (227.9 to 25.9) 0.003
Model 6: fully adjusted 212.8 (225.1 to 20.5) 0.040
Model 7: fully adjusted 1 nitroglycerin-mediated dilation 214.8 (225.7 to 23.8) 0.008
Standard model: determinant under consideration 1 age, sex, glucose tolerance status, baseline diameter,
and increase in peak systolic velocity. Fully adjusted model: standard model 1 prior CVD, Framingham risk score,
(micro)albuminuria, and waist circumference. Regression coefficients are expressed as absolute change in diam-
eter (in mm) per 1 SD increase of the independent variable to facilitate direct comparison. Significant associations
are printed in bold.
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sumption of alcohol may have an antiatherogenic effect.
Paradoxically, Schroder et al. (32) observed a positive rela-
tion between oxLDL concentrations and moderate alcohol
consumption. In the present study, moderate alcohol con-
sumption was negatively associated with the oxLDL/LDL-c
and oxLDL/apoB100 ratios. However, after full adjust-
ment, this association was only borderline significant in
the model for oxLDL/apoB100. Likewise, current smoking
was positively associated with oxLDL with borderline signif-
icance in univariate analysis, but did not contribute to the
multivariate models.
To investigate whether adjustment of oxLDL levels for
LDL particle number may be relevant in clinical studies,
we explored the impact of adjustment on the relation be-
tween oxLDL and FMD. Neither LDL-c nor apoB100 were
significantly related to FMD, and oxLDL showed a bor-
derline significant negative association. In contrast, the
oxLDL/apoB100 ratio showed a significant, negative asso-
ciation with FMD, even after adjustment for other risk fac-
tors or NMD. These results strongly suggest that this ratio
yields more information than the separate variables. There-
fore, using the oxLDL/apoB100 ratio rather than the
oxLDL level is not equivalent to statistical adjustment of
the relation between oxLDL and FMD for apoB100.
Although our study was not designed to unravel the
mechanisms linking elevated levels of oxLDL and FMD,
our data allow drawing some tentative conclusions. Forma-
tion of oxLDL is promoted by oxidative stress, but oxLDL
itself has also been identified as a potent stimulus for vas-
cular free radical formation (33). This may lead to a vicious
circle, making it virtually impossible to separate cause and
effect. The inverse relation between oxLDL levels and FMD
may indicate that oxidative stress is a common antecedent
of diminished vasodilation and LDL oxidation. A second
potential mechanism is that oxLDL itself, by inflicting dam-
age to the endothelium, has a direct adverse effect on vaso-
dilation. It should be noted that both mechanisms are not
mutually exclusive but may act in concert. Our data, show-
ing that the level of oxidative stress, as indicated by the
oxLDL/apoB100 ratio, is a stronger determinant of FMD
than the absolute concentration of oxLDL, supports a ma-
jor role for the first mechanism.
The lack of a significant association between oxLDL/
apoB100 and NMD suggests that the effect is mainly endo-
thelium dependent. This is corroborated by the fact that
the strength of the association between oxLDL/apoB100
and FMD was not attenuated by adjustment for NMD.
Nitric oxide is the most important endothelium-derived
vasodilator in conduit arteries, and it is well known that
scavenging of nitric oxide by reactive oxygen species, in par-
ticular superoxide, reduces the bioavailability of nitric
oxide in the vascular wall. Overall, the results of this study
support the notion that the oxLDL/apoB100 ratio is an in-
dicator of vascular production of reactive oxygen species,
which by scavenging nitric oxide, limit vasodilation. How-
ever, our data do not fully rule out the possibility that oxLDL
itself also has an adverse effect on vasodilation.
Our study had some limitations. First, the study popula-
tion was limited to elderly Caucasians, and therefore the
results may be different in other ethnic and age groups.
Second, exclusion of subjects using lipid-lowering medica-
tion probably has led to selection of subjects with a low
cardiovascular risk profile. This may have resulted in an
underestimation of the strength of associations between
oxLDL and CVD risk factors and vascular function.
Third, the assay used to measure oxLDL specifically de-
tects epitopes of oxidized apoB100. However, oxLDL is not
a single homogeneous entity, and assays detecting epitopes
on other constituents of oxLDL may yield different results.
A major strength of our study is that LDL-c was measured
directly and not estimated by Friedewald formula. In addi-
tion, we had a large array of clinical and biochemical vari-
ables at our disposal to adjust for possible confounding.
Our data confirm that LDL-c and more prominently the
number of LDL particles, estimated as apoB100, is a strong
determinant of circulating oxLDL levels. The oxLDL/
LDL-c and oxLDL/apoB100 ratios, which express the level
of LDL oxidation independent of particle number, were
shown to provide information beyond oxLDL, LDL-c,
and apoB100, as evidenced by the independent association
of these ratios with endothelium-dependent dilation of the
brachial artery.
We wish to thank Bert Volwater for technical assistance.
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